Cybin Inc. Appoints Co-Founder Eric So as Interim CEO Following Drysdale's Departure

Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) has announced a significant leadership transition, with co-founder and president Eric So assuming the role of interim chief executive officer effective September 2, 2025, following the resignation of Doug Drysdale. The board of directors has established a committee to conduct a comprehensive search for a permanent CEO who will guide the company through its commercialization phase, while So focuses on advancing Cybin's promising clinical pipeline and maintaining operational stability during this transitional period.

The leadership change comes at a critical juncture for Cybin, a late-stage neuropsychiatry company dedicated to transforming mental healthcare through innovative treatment options. The company's clinical development programs include CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for adjunctive treatment of major depressive disorder. This investigational therapy has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential significance in addressing the substantial unmet needs in mental health treatment. Additional information about the company's developments can be found at https://ibn.fm/CYBN.

Complementing CYB003 is CYB004, Cybin's proprietary deuterated N, N-dimethyltryptamine molecule undergoing Phase 2 evaluation for generalized anxiety disorder. The company maintains an extensive research pipeline focused on investigational 5-HT-receptor compounds, positioning itself at the forefront of novel psychiatric treatment development. Founded in 2019, Cybin maintains operational presence across Canada, the United States, the United Kingdom, and Ireland, reflecting its global approach to mental health innovation. The leadership transition ensures that these critical programs continue progressing without disruption during the executive search process.

The appointment of Eric So as interim CEO provides continuity given his foundational role in establishing Cybin and his deep understanding of the company's strategic direction and scientific objectives. His interim leadership will be crucial in maintaining momentum for Cybin's clinical trials and research initiatives while the board committee identifies a permanent CEO capable of steering the company through anticipated commercialization phases. This leadership stability is particularly important given the advanced stage of Cybin's lead programs and the competitive landscape of psychedelic-inspired therapeutics. Further details about corporate communications and investor relations can be accessed through specialized platforms at https://www.InvestorWire.com.

The timing of this executive transition underscores the importance of experienced leadership in navigating the complex regulatory and development pathways for novel psychiatric treatments. With mental health disorders affecting millions worldwide and existing treatments often providing inadequate relief, Cybin's work represents a potentially transformative approach to neuropsychiatry. The company's focus on developing next-generation treatments with promising class-leading data aims to address the substantial gap in effective mental healthcare options, making leadership continuity during this period essential for maintaining investor confidence and scientific progress.